-
Circle the dates on your calendar for Reproductive Health 2008, the annual meeting for the Association of Reproductive Health Professionals (ARHP), Planned Parenthood Federation of America, and the Society of Family Planning. The meeting is scheduled for Sept. 17-20 in Washington, DC.
-
With high and rising levels of uninsurance and health care costs, federal and state policy-makers have taken note.
-
Research is eyeing an oral contraceptive (OC) formulation with a new progestin: dienogest. Results of an efficacy trial, presented at the 2008 Clinical Meeting of the American College of Obstetricians and Gynecologists (ACOG), indicate the formulation is effective, safe, and well tolerated.
-
The next patient in your office is a 25-year-old mother of two. She's using oral contraceptives (OCs) for birth control, but when you ask her about her method use, she admits she's having problems remembering to take her daily pill.
-
With recent findings that 4% of young women between the ages of 14 and 19 in the United States are infected with chlamydia, public health officials are stepping up efforts to screen more adolescent girls for the sexually transmitted disease (STD).
-
Ceftobiprole, a novel broad-spectrum cephalosporin with activity against MRSA, was non-inferior to vancomycin plus ceftazidime in a study of complicated skin and skin-structure infections. This is the first β-lactam with reliable activity against methicillin resistant Staphylococcus aureus (MRSA) to be evaluated in advanced-stage clinical trials.
-
Elevated troponin i is a nonspecific finding, but suggests a poor prognosis regardless of its cause.
-
Institution of a daily pharmacist-enforced intervention designed to improve adherence to sedation guidelines decreased the duration of mechanical ventilation and ICU stay.
-
In this review of patients admitted to the ICU with acute respiratory failure secondary to COPD exacerbation or cardiogenic pulmonary edema, nearly two-thirds of patients who apparently met criteria for noninvasive ventilation (NIV) were intubated without a trial of NIV.
-
Randomized studies of neuroprotective agents for ischemic stroke have resulted in a series of failures, as multiple agents, promising in animal models, have failed when applied to human subjects. By contrast, intracerebral hemorrhage (ICH) has been somewhat a "neglected stepsister" when compared to ischemic stroke; it has been studied minimally, despite its high morbidity and mortality.